In this interactive session, Life Sciences CEOs will explain what their concerns are while evaluating opportunities outside their organizations and maximizing the opportunities inside their organizations. Topics will include:
- How does a CEO incorporate shareholder valuation into the due diligence process?
- How do you measure acceptable risk?
- What due diligence factors do you use in selecting a partner for a collaboration agreement?
Panelists include: George Daniloff, CEO, Carbylan BioSurgery; Dinesh V. Patel, Ph.D., President and CEO, Arête Therapeutics; Tom Moran, Of Counsel, Foley; Jay Sheppard, President and Chief Executive Officer, Relypsa, Inc.; and James A. D. Smith, President and Chief Executive Officer, Genelabs.
Related Insights
May 30, 2025
Foley Career Perspectives
Foley Mental Health Month Program: Enhancing Performance Through High-Quality Connections
Foley & Lardner endeavors to create a high-performance culture that also prioritizes well-being — a culture where every member of the…
May 29, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
May 29, 2025
Foley Viewpoints
Supreme Court Clarifies Scope of Federal Fraud Statutes in Connection with False DBE Reporting on Federally Funded Projects
On May 22, 2025, the U.S. Supreme Court issued a significant decision in Kousisis v. United States, affirming a six-year prison sentence for a contractor convicted of federal wire fraud for misrepresenting use of a disadvantaged business enterprise supplier on a project.